1. The holder of the marketing authorisation for a medicinal product for human use shall ensure that all suspected serious adverse reactions to a medicinal product authorised in accordance with this Regulation occurring within the Community which a health-care professional brings to his attention are recorded and reported promptly to Member States within the territory of which the incident occurred, and no later than 15 days following the receipt of the informationAgency shall, in collaboration with the Member States and the Commission, set up and maintain a database and data processing network (hereinafter the ‘Eudravigilance database’) to collate pharmacovigilance information regarding medicinal products authorised in the Union and to allow competent authorities to access that information simultaneously and to share it.
The holder of the marketing authorisation Eudravigilance database shall record any othercontain information on suspected serious adverse reactions occurring within the Community, in accordance with the guide referred to in Article 26, of which he may reasonably be expected to be aware, and promptly notify the competent authority of Member States in human beings arising from use of the medicinal product within the terms of the marketing authorisation as well as from uses outside the terms of the marketing authorisation, and on those occurring in the territory of which the incident occurred and the Agency, and no later than 15 days following receipt of the informationcourse of post-authorisation studies with the medicinal product or associated with occupational exposure.
2. The holder of the marketing authorisation for a medicinal product for human use Agency shall ensure that all suspected serious unexpected adverse reactions and any suspected transmission via a medicinal product of any infectious agent occurring in the territory of a third country are reported promptly to , in collaboration with the Member States and the Agency, and no later than 15 days following receipt of the information. The Commission shall adopt provisions for the reporting of suspected unexpected adverse reactions which are not serious, whether occurring in the Community or in a third country. Those measures, designed to amend non-essential elements of this regulation by supplementing it, Commission, draw up the functional specifications for the Eudravigilance database, together with a timeframe for their implementation.
The Agency shall prepare an annual report on the Eudravigilance database and send it to the European Parliament, the Council and the Commission. The first annual report shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 87(2a).
Save in exceptional circumstances, these reactionsprepared by 2 January 2013.
The Management Board of the Agency shall be transmitted electronically in the form of a on the basis of an independent audit report and in accordance with the guide referred to in Article 26.
3. The holder of the marketing authorisation for a medicinal product for human use shall maintain detailed records of all suspected adverse reactions within or outside the Community which are reported to him by a health-care professional.
Unless other requirements have been laid down as a condition for the grantingthat takes into account the recommendation of the Pharmacovigilance Risk Assessment Committee confirm and announce when the Eudravigilance database has achieved full functionality and the system meets the functional specifications drawn up pursuant to the first subparagraph.
Any substantial change to the Eudravigilance database and the functional specifications shall take into account the recommendations of the marketing authorisation by the Community, these records Pharmacovigilance Risk Assessment Committee.
The Eudravigilance database shall be submitted, in the form of a periodic safety update report, fully accessible to the competent authorities of the Member States and to the Agency and Member States immediately upon request or at least every six months after authorisation until the placing on the market. Periodic safety update reports the Commission. It shall also be accessible to marketing authorisation holders to the extent necessary for them to comply with their pharmacovigilance obligations.
The Agency shall also be submitted immediately upon request or at least every six months during the first two years following the initial placing on the Community market and once a year for the following two years. Thereafter, the reports shall be submitted at three-yearly intervals, or immediately upon request.
These reports shall be accompanied by a scientific evaluation, particularly of the risk-benefit balance of the medicinal product.
4. The Commission may lay down provisions to amend paragraph 3 in view of experience gainedensure that healthcare professionals and the public have appropriate levels of access to the Eudravigilance database, while guaranteeing personal data protection. The Agency shall work together with all stakeholders, including research institutions, healthcare professionals, and patient and consumer organisations, in order to define the ‘appropriate level of access’ for healthcare professionals and the public to the Eudravigilance database.
The data held on the Eudravigilance database shall be made publicly accessible in an aggregated format together with its operation. Those measures, designed to amend non-essential elements of this regulation, shall be adopted in accordance an explanation of how to interpret the data.
3. The Agency shall, in collaboration either with the regulatory procedure with scrutiny referred to in Article 87(2a).
5. The holder of a marketing authorisation may not communicate information relating to pharmacovigilance concerns to the general public in relation to its authorised medicinal product without giving prior or simultaneous notification to the Agency.
In any case, the marketing authorisation holder shall ensure that such information is presented objectively and is not misleading.
Member States shall take the necessary measures to ensure that a marketing authorisation holder who fails to discharge these obligations is subject to effective, proportionate and dissuasive penaltiesmarketing authorisation holder or with the Member State that submitted an individual suspected adverse reaction report to the Eudravigilance database, be responsible for operating procedures that ensure the quality and integrity of the information collected in the Eudravigilance database.
4. Individual suspected adverse reaction reports and follow-ups submitted to the Eudravigilance database by marketing authorisation holders shall be transmitted electronically upon receipt to the competent authority of the Member State where the reaction occurred.